Beam Therapeutics Inc. — 2022 Q2 Form 10-Q Summary
Business context and reporting period
Beam Therapeutics is an early-stage biotechnology company developing precision genetic medicines based on base-editing technology and multiple delivery platforms, including electroporation, lipid nanoparticles and AAV vectors. The filing covers the three and six months ended June 30, 2022, and was filed August 9, 2022. Beam has not generated product revenue and remains dependent on collaboration revenue and external financing.
Key financial metrics
| Metric | Three months ended June 30 | Six months ended June 30 |
|---|---|---|
| License and collaboration revenue | $16.7 million, versus $0.006 million in 2021 | $25.1 million, versus $0.012 million in 2021 |
| Research and development expense | $74.6 million, up $29.0 million | $140.0 million, down $95.7 million |
| General and administrative expense | $24.1 million, up $10.7 million | $43.3 million, up $19.6 million |
| Loss from operations | $82.0 million | $158.2 million |
| Net loss | $72.0 million, or $1.02 per share | $141.2 million, or $2.03 per share |
| Net cash provided by operating activities | $166.2 million for the six-month period |
Operating and net margins were negative; revenue is not yet representative of product commercialization economics. The six-month operating cash inflow was primarily driven by collection of the $300.0 million Pfizer collaboration receivable, rather than recurring operating profitability.
- Cash and cash equivalents were $265.6 million at June 30, 2022; marketable securities were $900.5 million; total cash, cash equivalents and marketable securities were approximately $1.17 billion.
- Cash, cash equivalents and restricted cash declined to $278.4 million from $572.7 million at December 31, 2021, reflecting investment purchases, capital expenditures and operating uses.
- Net cash used in investing activities was $538.6 million, including $28.9 million of property and equipment purchases and net purchases of marketable securities.
- Net cash provided by financing activities was $78.0 million, primarily from equity offerings, ESPP proceeds and option exercises.
- Total liabilities were $618.2 million, including $173.5 million of operating lease liabilities, $4.2 million of equipment financing liabilities and $47.4 million of success-payment and contingent-consideration liabilities.
- Accumulated deficit was $909.4 million. Management expects operating losses and negative operating cash flows for the foreseeable future.
Material changes versus the prior comparable period
- Revenue increased substantially because Beam recognized revenue under the Pfizer and Apellis collaborations, including the $300.0 million Pfizer upfront payment and the $25.0 million Apellis anniversary payment received in 2022. The filing states that $20.6 million of Pfizer revenue and $4.5 million of Apellis revenue were recognized in the first six months.
- Six-month research and development expense decreased primarily because the prior-year period included a $155.0 million noncash write-off of acquired in-process research and development related to Guide. Excluding that item, current-period R&D spending increased as programs advanced and the workforce expanded.
- Second-quarter R&D expense increased 63.6% year over year to $74.6 million, driven by personnel, facilities, stock-based compensation, laboratory supplies, outsourced services and IND-enabling work.
- General and administrative expense increased 82.9% for the quarter and 82.9% for the six-month period, reflecting higher personnel and stock-based compensation costs, public-company expenses and a $3.4 million accrual related to a research-institution dispute.
- Net loss improved year over year, but the comparison benefited from the prior-year Guide write-off and favorable changes in derivative liabilities. In 2022, Beam recorded $25.8 million of income from the fair-value decrease in success-payment liabilities, compared with $44.2 million of expense in 2021.
- Beam sold additional common stock under its ATM facility. As of June 30, 2022, cumulative gross proceeds under the amended facility were $289.3 million, before commissions and offering expenses.
Guidance, outlook, commentary and risks
- Management expects cash, cash equivalents and marketable securities at June 30, 2022 to fund operations for at least the next 12 months, but states that additional financing will be required to support continuing operations and growth.
- Beam expected to enroll the first subject in the BEACON-101 Phase 1/2 trial of BEAM-101 for sickle cell disease in the second half of 2022.
- Beam expected to submit an IND for BEAM-102 for sickle cell disease and begin IND-enabling studies for BEAM-301 for GSDIa in the second half of 2022.
- Beam expected its 100,000-square-foot cGMP manufacturing facility in North Carolina to be operational in the first quarter of 2023. The facility lease carries estimated undiscounted payments of approximately $69.0 million over 15 years beginning in 2023.
- Beam submitted the BEAM-201 IND at the end of June 2022. Subsequent to quarter-end, on July 29, 2022, the FDA informed Beam that the IND had been placed on clinical hold. Beam expected a formal hold letter and further discussions with the FDA.
- Because additional edits may be needed to achieve a fully allogeneic CAR-T product, management did not expect to nominate a second CAR-T development candidate in 2022 and anticipated further updates in 2023.
- Key risks include clinical and regulatory failure, the BEAM-201 clinical hold, manufacturing execution, dependence on collaborations, need for additional capital, intellectual-property interference and infringement proceedings, contingent milestone obligations, research-institution claims, supply-chain disruption and COVID-19-related impacts.
- Beam disclosed an ongoing confidentiality and trade-secret dispute with a research institution. Management believes the allegations are without merit but cannot predict the outcome or potential financial impact.
- Guide acquisition-related contingent consideration includes up to $100.0 million of technology milestones and $220.0 million of product milestones, payable in common stock.
Most important facts for investors to verify
- Whether the FDA clinical hold on BEAM-201 is resolved, the requested remediation is achievable and the program timeline or costs change materially.
- Whether BEACON-101 begins on schedule and whether BEAM-102 and BEAM-301 meet their stated IND-enabling and filing milestones.
- The sustainability of collaboration revenue and the timing of Pfizer opt-in decisions, future milestones and royalty opportunities.
- Whether the approximately $1.17 billion of cash and marketable securities remains sufficient as R&D, clinical, manufacturing and lease expenditures increase.
- Future equity issuance, dilution and the need for additional financing before product revenue is generated.
- Progress, cost and operational readiness of the North Carolina manufacturing facility.
- Developments in the disclosed patent interferences, European opposition proceedings and research-institution confidentiality dispute.